Search

Scleroderma Life Hacks

Video series featuring people living with scleroderma using everyday items in different ways to help them manage their symptoms. Part of the global 'More Than Scleroderma' initiative developed by Boehringer Ingelheim, with support from patient organi

The geography of pet parasites is changing

Climate change facilitates new pet parasites way beyond ticks and flea bites in dogs and cats

FDA accepts new chronic kidney disease treatment application

ArisGlobal acquires Boehringer Ingelheim technology

Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal

The GPP Charter

The GPP Charter defines a collaborative approach to identifying common goals for the GPP community

Digital innovation: Our digital pipeline is only growing

BRASS, a software advancing patient safety and developed fully in-house, has been sold. This is proof: our digital innovations are in demand.

Brigitte Fuhr

Brigitte Fuhr, our Head of Central Data Science, joined our team to make millions of lives better. Now she’s working on a global program that will transform our ability to develop ground-breaking treatments.

Zongertinib positive results non-small cell lung cancer

Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients

Big hearts united to help animals in Ukraine

Veterinaries volunteer at the Polish-Ukrainian border to help welcome Refugees and their animals. Refugees don’t rest until their animals are safe.

Advancing green chemistry for more sustainable medicines

By applying the principles of eco-design and green chemistry, we developed an innovative manufacturing process with reduced environmental footprint.

The Unwearable Collection™ Evolution

Get ready for the next stage of The Unwearable Collection™

10 tips cat friendly veterinary clinics

Here are 10 simple steps you can take to make feline patients feel at ease at your practice.

Partnership for first-in-class cancer and CRM treatments

Boehringer Ingelheim partners with OSE Immunotherapeutics to develop first-in-class cancer and CRM treatments

New cancer therapeutics collaboration with 3T Bio

Boehringer Ingelheim and 3T Biosciences collaborate to discover and develop next-generation cancer therapies to address high unmet patient needs

Global mobility

We are a global company with a global outlook. We welcome the breadth of perspective that international experience brings to our teams.

CAROLINA-CARMELINA-Asia-analysis

CAROLINA® and CARMELINA® outcome trial subgroup analyses demonstrate cardiovascular and renal safety data in Asian adults with type 2 diabetes

Facts about the INPULSIS™ trials

New Therapeutic Antibody Discovery Collaboration

Proprietary antibody libraries to help discover therapeutic antibodies against multiple targets

clinical-collaboration-with-Amgen

Collaboration to study Boehringer Ingelheim’s SOS1::pan-KRAS Inhibitor in combination with Amgen’s KRASG12C Inhibitor

Option to Acquire Trutino Biosciences

Netherton Syndrome

Information on Netherton Syndrome, a severe, ultra-rare multisystem disorder which has a life-altering impact across a person’s life.

Geographic Atrophy treatment to move to Phase II

Geographic Atrophy treatment BI 771716 to move to Phase II, following positive Phase I results

Social Media Data Privacy and Cookies Statement

Ukraine Help: We fly, we bike, we accommodate

The solidarity for Ukraine from Boehringer Ingelheim employees is incredible. Equally impressive is their practical help.

Sustainable medicines that help minimize environmental impact

How we collaborate with renowned experts to lead the way in reducing solvent waste, as part of our efforts to embed sustainability into our core business.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers